Conference Coverage
10 days ago
5 key trial insights from ESMO 2025Latest News
Nov 05, 2025 | News
Phase 2 trial of IL-15 superagonist launches in NMIBC
What income and estate tax provisions are in the One Big Beautiful Bill Act?
Nov 05, 2025
Trial launches of Optilume drug-coated balloon for benign ureteric strictures
Nov 04, 2025
FDA approves fosfomycin for complicated urinary tract infections
Nov 04, 2025
Pearls & Perspectives: Testosterone, Muscle, and Healthspan with Mohit Khera, MD, MBA, MPH
Nov 04, 2025
Advertisement
Shorts
1:10
Jen-Jane Liu, MD, discusses evaluation of detalimogene voraplasmid in NMIBC
a day ago
by
Jen-Jane Liu, MD
1:05
Angela B. Smith, MD, MS, on optimizing conversations with patients with MIBC
2 days ago
by
Angela B. Smith, MD, MS
0:50
Stephen Freedland, MD, discusses significance of EMBARK OS data
3 days ago
by
Stephen J. Freedland, MD
0:47
Monique Roobol, PhD, MSc, on what ERSPC data reveal about PSA screening
6 days ago
by
Monique Roobol, PhD, MSc
1:15
Pedro C. Barata, MD, MSc, FACP, recaps prostate cancer research at ESMO 2025
7 days ago
by
Pedro Barata, MD, MSc, FACP
0:51
Kim Chi, MD, discusses the PR.21 study of lutetium vs docetaxel in mCRPC
8 days ago
by
Kim Nguyen Chi, MD, FRCPC
2:03
Sean P. Collins, MD, PhD, discusses rectal spacers and biochemical recurrence in prostate cancer
9 days ago
by
Sean P. Collins, MD, PhD
1:26
Leila Momtazi-Mar discusses sperm retrieval in patients with Klinefelter Syndrome
10 days ago
by
Leila Momtazi-Mar
0:49
Sevann Helo, MD, offers advice on residency interviews
13 days ago
by
Sevann Helo, MD
0:50
Srikala Sridhar, MD, discusses ALPACA study in penile cancer
18 days ago
by
Srikala Sridhar, MD
Dr. Laura Sena discusses ongoing trials of bipolar androgen therapy in prostate cancer
Bipolar androgen therapy is being explored in trials with enzalutamide (Xtandi), olaparib (Lynparza), and nivolumab (Opdivo), explains Laura Sena MD, PhD.
Podcasts
Videos
Urology Times Digital Edition
"Suctioning technology for mini-PCNL is an improvement on relying on passive outflow," says Mantu Gupta, MD.
The approval is supported by data from the phase 3 MK-3475A-D77 trial.
The Altaviva device is a minimally invasive implantable tibial neuromodulation therapy for patients with urge urinary incontinence.
According to the authors, these findings suggest that FloStent could serve as an effective interim solution for men who are awaiting TURP.
Recent data suggests a lack of knowledge among primary care providers on the value of prostate specific antigen testing, particularly for patients in high-risk groups.
According to the authors, these findings suggest that biparametric MRI could become the new standard of care for prostate cancer diagnosis.
Two-year outcomes from the ASPIRE trial continued to show that the SURE procedure led to significantly reduced health care consumption events compared with ureteroscopy.
The NDA is supported by data from a phase 3 trial, which demonstrated a 75% complete response rate at 3 months.
Siamak Daneshmand, MD, shares his thoughts on the impact of the gemcitabine releasing system for clinical practice.
The registrational trial is aiming to expand the indications for Illuccix and Gozellix to include use in prostate cancer diagnosis.
Continuing Medical Education
Advertisement
All News
Advertisement
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Taylor Goodstein, MD, and Pretesh Patel, MD, explore how image guidance and adaptive radiation planning have revolutionized precision, even allowing real-time treatment plan adjustments.
A recap of the FDA submissions and regulatory decisions in urology from October 2025.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Christof Vulsteke, MD, PhD, discusses results from the KEYNOTE-905 trial, evaluating perioperative EV/pembrolizumab in cisplatin-ineligible MIBC.
In this episode, Adam Weiner, MD, and Michael Leapman, MD, discuss the current state of active surveillance for intermediate-risk prostate cancer.
According to the authors, immune-mediated adverse events were manageable and consistent with the known profiles for ICIs.
Tatem discusses his latest research on treating ventral curvature in Peyronie disease using collagenase clostridium histolyticum (Xiaflex).
The UroOnc Minute, hosted by Adam Weiner, MD, is the latest multimedia program from Urology Times.
Avvio Medical plans to submit a de novo application for clearance of the device in early 2026.
Advertisement
Scott B. Sellinger, MD, FACS, discusses the challenges facing urologists, the loss of telehealth flexibility, and why bipartisan action remains urgent.
Merck plans to share these data with regulatory authorities worldwide.
The key finding was that men who received rectal spacers had a 50% lower risk of biochemical failure.
The phase 3 LITESPARK-011 trial has met its primary end point.
According to the authors, this combination represents a potential new standard of care for this patient population.
Advertisement
Advertisement
Trending on Urology Times
1
What income and estate tax provisions are in the One Big Beautiful Bill Act?
2
Phase 2 trial of IL-15 superagonist launches in NMIBC
3
FDA approves fosfomycin for complicated urinary tract infections
4
Jen-Jane Liu, MD, highlights clinical advantages of detalimogene voraplasmid in NMIBC
5
